GoAI
Get started
Aclarion, Inc. logo

Aclarion, Inc.

ACON

NASDAQHealthcareMedical - Healthcare Information Services

Open in GoAI

Previous close

$2.71

+$0.02 · +0.74%

Aug 21, 4:00 PM ET

ACON company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

69

Undervalued

Momentum

21

Weakening

Sentiment

54

Mixed

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.

Industry
Medical - Healthcare Information Services
Sector
Healthcare
Headquarters
US
CEO
Brent Ness
Listed since
Apr 22, 2022
Employees
11

Market position

Day range

Current $2.71

52-week range

Current $2.71

Open
$2.68
Previous close
$2.69
Volume
44.41K
0.55× average
Average volume
80.41K
Average daily volume
Market cap
1.45M USD
Beta
1.22
Market reference 1
50-day average
$2.6594
+1.90% above average
200-day average
$3.7769
-28.25% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-9.57M USD
P/E (TTM)
-0.36×
P/B (TTM)
0.39×
P/S (TTM)
17.25×
EV / EBITDA
1.37×
Earnings yield
-295.57%
Free cash flow yield
-293.61%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-50.96%
Operating margin
-11592.14%
Net margin
-10978.48%
Return on equity
-56.36%
Return on assets
-52.91%
Return on invested capital
-54.95%

Financial health

Debt / equity
0×
Current ratio
14.81×
Altman Z-score
-4.77
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1529%-4588%-10706%-16823%Gross margin, FY2021: -14.73%Gross margin, FY2022: -8.03%Gross margin, FY2023: -0.43%Gross margin, FY2024: -183.81%Gross margin, FY2025: -291.27%Operating margin, FY2021: -4897.89%Operating margin, FY2022: -9201.19%Operating margin, FY2023: -6466.48%Operating margin, FY2024: -12057.23%Operating margin, FY2025: -9312.55%Net margin, FY2021: -8210.53%Net margin, FY2022: -11694.45%Net margin, FY2023: -6513.41%Net margin, FY2024: -15293.78%Net margin, FY2025: -9551.87%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -14.73%. Gross margin FY2022 -8.03%. Gross margin FY2023 -0.43%. Gross margin FY2024 -183.81%. Gross margin FY2025 -291.27%. Operating margin FY2021 -4897.89%. Operating margin FY2022 -9201.19%. Operating margin FY2023 -6466.48%. Operating margin FY2024 -12057.23%. Operating margin FY2025 -9312.55%. Net margin FY2021 -8210.53%. Net margin FY2022 -11694.45%. Net margin FY2023 -6513.41%. Net margin FY2024 -15293.78%. Net margin FY2025 -9551.87%.

Income trends

Revenue

75.73K USD+65.62%

Operating income

−7.05M USD-27.92%

Net income

−7.23M USD-3.44%
Income trends across reported periods806.67K USD−2.12M USD−5.04M USD−7.96M USDRevenue, FY2021: 60.29K USDRevenue, FY2022: 60.44K USDRevenue, FY2023: 75.4K USDRevenue, FY2024: 45.72K USDRevenue, FY2025: 75.73K USDOperating income, FY2021: −2.95M USDOperating income, FY2022: −5.56M USDOperating income, FY2023: −4.88M USDOperating income, FY2024: −5.51M USDOperating income, FY2025: −7.05M USDNet income, FY2021: −4.95M USDNet income, FY2022: −7.07M USDNet income, FY2023: −4.91M USDNet income, FY2024: −6.99M USDNet income, FY2025: −7.23M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 60.29K USD. Revenue FY2022 60.44K USD. Revenue FY2023 75.4K USD. Revenue FY2024 45.72K USD. Revenue FY2025 75.73K USD. Operating income FY2021 −2.95M USD. Operating income FY2022 −5.56M USD. Operating income FY2023 −4.88M USD. Operating income FY2024 −5.51M USD. Operating income FY2025 −7.05M USD. Net income FY2021 −4.95M USD. Net income FY2022 −7.07M USD. Net income FY2023 −4.91M USD. Net income FY2024 −6.99M USD. Net income FY2025 −7.23M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue75.73K USD45.72K USD75.4K USD60.44K USD60.29K USD
Cost of goods sold296.31K USD129.77K USD75.73K USD65.3K USD69.18K USD
Gross profit−220.58K USD−84.04K USD−324 USD−4.85K USD−8.88K USD
Research and development1.03T USD888.77K USD873.34K USD1.07M USD787.85K USD
Selling, general, and administrative6.03T USD4.59M USD4M USD4.49M USD2.16M USD
Operating expenses6.83M USD5.43M USD4.88M USD5.56M USD2.94M USD
Interest income411.06K USD318 USD172 USD2.51K USD—
Interest expense—535.47K USD608.29K USD1.51M USD476.48K USD
Depreciation and amortization227.41K USD193.14K USD162.67K USD143.62K USD186.39K USD
Operating income−7.05M USD−5.51M USD−4.88M USD−5.56M USD−2.95M USD
Net income−7.23M USD−6.99M USD−4.91M USD−7.07M USD−4.95M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 7 misses, 1 met estimate
Average EPS surprise
-206895.47%
11 comparable reports
Latest EPS result
-1.12
Estimate -1.05 · Miss by 6.67%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.89-559.26-1,117.63-1,676Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MetQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -1,551.93, estimate -50, surprise -3003.86%, Miss. Q2 2025, reported May 15, 2025: actual -9.32, estimate -1,447.2, surprise +99.36%, Beat. Q3 2025, reported Aug 14, 2025: actual -2.75, estimate -2.26, surprise -21.68%, Miss. Q4 2025, reported Nov 12, 2025: actual -2.93, estimate -2.64, surprise -10.98%, Miss. Q1 2026, reported Feb 25, 2026: actual -3.6, estimate -3.6, surprise 0.00%, Met estimate. Q2 2026, reported May 21, 2026: actual -1.34, estimate -1.55, surprise +13.55%, Beat. Q3 2026, reported Aug 6, 2026: actual -1.12, estimate -1.05, surprise -6.67%, Miss. Q4 2026, reported Nov 11, 2026: actual —, estimate -1.05, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates42.38K31.15K19.93K8.7KQ1 '25No estimateQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MetQ2 '26MetQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual 10.23K USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 15, 2025: actual 18.99K USD, estimate 20K USD, surprise -5.04%, Miss. Q3 2025, reported Aug 14, 2025: actual 19.32K USD, estimate 30K USD, surprise -35.60%, Miss. Q4 2025, reported Nov 12, 2025: actual 18.94K USD, estimate 19K USD, surprise -0.31%, Miss. Q1 2026, reported Feb 25, 2026: actual 20K USD, estimate 20K USD, surprise 0.00%, Met estimate. Q2 2026, reported May 21, 2026: actual 20K USD, estimate 20K USD, surprise 0.00%, Met estimate. Q3 2026, reported Aug 6, 2026: actual 25.21K USD, estimate 30K USD, surprise -15.97%, Miss. Q4 2026, reported Nov 11, 2026: actual —, estimate 40K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

2 institutions
Maxim GroupdowngradeBuyHold

Corporate actions

Corporate action history

Stock split

Effective Mar 28, 2025

1:27

Stock split

Effective Jan 30, 2025

1:335

Stock split

Effective Jan 4, 2024

1:16

ACON peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ACON

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
15.26K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research ACON

research.disclaimer